P1–386: Cross‐species analysis of cerebrospinal fluid (CSF) beta‐amyloid reductions by the BACE1 inhibitor PF‐05297909 indicates species differences in PK/PD relationships: Relevance to clinical translation
Éva Hajós‐Korcsok(Pfizer (United States)), David Riddell(Eli Lilly (United States)), Charles E. Nolan(Pfizer (United States)), Sridhar Duvvuri(Cerevel Therapeutics (United States)), J. Simon Bell(Monash University), Ashley Robshaw(Pfizer (United States)), Curt Christoffersen(Pfizer (United States)), Cheng Chang(Pfizer (United States)), Jinhua Liu(Pfizer (United States)), Brian T. O’Neill(Pfizer (United States)), Timothy Nicholas(Pfizer (United States)), Yasong Lu(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States))
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302
The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
|Molecular and Cellular Neuroscience|2007|248